{"id":283,"date":"2019-10-08T23:07:02","date_gmt":"2019-10-08T21:07:02","guid":{"rendered":"https:\/\/porphyria.network\/IPPN\/?p=283"},"modified":"2021-07-20T08:26:29","modified_gmt":"2021-07-20T06:26:29","slug":"the-fda-approves-afamelanotide-for-epp","status":"publish","type":"post","link":"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/","title":{"rendered":"The FDA approves afamelanotide for EPP!"},"content":{"rendered":"\n<p>The IPPN is delighted by today\u2018s FDA approval of afamelanotide, a significant milestone in a long, too long, and challenging journey to give EPP patients access to this life-changing therapy. While afamelanotide\u2018s manufacturer plans for distribution and works to secure reimbursement in the US, the approval is already a great achievement for EPP patients in the US and beyond. The IPPN hopes that it will provide momentum in accelerating access to many more patients worldwide and commits to further contributing to this goal.<\/p>\n\n\n\n<p>For now, let us savor the moment!<\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-increase-pain-free-light-exposure-patients-rare-disorder\">FDA News Release on Afamelanotide Approval<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The IPPN is delighted by today\u2018s FDA approval of afamelanotide, a significant milestone in a long, too long, and challenging journey to give EPP patients access to this life-changing therapy. While afamelanotide\u2018s manufacturer plans for distribution and works to secure reimbursement in the US, the approval is already a great achievement for EPP patients in&hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[31],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.6.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The FDA approves afamelanotide for EPP! - International Porphyria Patient Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The FDA approves afamelanotide for EPP! - International Porphyria Patient Network\" \/>\n<meta property=\"og:description\" content=\"The IPPN is delighted by today\u2018s FDA approval of afamelanotide, a significant milestone in a long, too long, and challenging journey to give EPP patients access to this life-changing therapy. While afamelanotide\u2018s manufacturer plans for distribution and works to secure reimbursement in the US, the approval is already a great achievement for EPP patients in&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/\" \/>\n<meta property=\"og:site_name\" content=\"International Porphyria Patient Network\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-08T21:07:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-20T06:26:29+00:00\" \/>\n<meta name=\"author\" content=\"Editorial Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Editorial Team\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/\"},\"author\":{\"name\":\"Editorial Team\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\"},\"headline\":\"The FDA approves afamelanotide for EPP!\",\"datePublished\":\"2019-10-08T21:07:02+00:00\",\"dateModified\":\"2021-07-20T06:26:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/\"},\"wordCount\":104,\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"articleSection\":[\"English\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/\",\"name\":\"The FDA approves afamelanotide for EPP! - International Porphyria Patient Network\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\"},\"datePublished\":\"2019-10-08T21:07:02+00:00\",\"dateModified\":\"2021-07-20T06:26:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/porphyria.network\/IPPN\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The FDA approves afamelanotide for EPP!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"name\":\"International Porphyria Patient Network\",\"description\":\"Welcome to the International Porphyria Patient Network\",\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\",\"name\":\"International Porphyria Patient Network\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"contentUrl\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"width\":671,\"height\":630,\"caption\":\"International Porphyria Patient Network\"},\"image\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\",\"name\":\"Editorial Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"caption\":\"Editorial Team\"},\"url\":\"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The FDA approves afamelanotide for EPP! - International Porphyria Patient Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/","og_locale":"en_US","og_type":"article","og_title":"The FDA approves afamelanotide for EPP! - International Porphyria Patient Network","og_description":"The IPPN is delighted by today\u2018s FDA approval of afamelanotide, a significant milestone in a long, too long, and challenging journey to give EPP patients access to this life-changing therapy. While afamelanotide\u2018s manufacturer plans for distribution and works to secure reimbursement in the US, the approval is already a great achievement for EPP patients in&hellip;","og_url":"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/","og_site_name":"International Porphyria Patient Network","article_published_time":"2019-10-08T21:07:02+00:00","article_modified_time":"2021-07-20T06:26:29+00:00","author":"Editorial Team","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Editorial Team"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/#article","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/"},"author":{"name":"Editorial Team","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765"},"headline":"The FDA approves afamelanotide for EPP!","datePublished":"2019-10-08T21:07:02+00:00","dateModified":"2021-07-20T06:26:29+00:00","mainEntityOfPage":{"@id":"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/"},"wordCount":104,"publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"articleSection":["English"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/","url":"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/","name":"The FDA approves afamelanotide for EPP! - International Porphyria Patient Network","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/#website"},"datePublished":"2019-10-08T21:07:02+00:00","dateModified":"2021-07-20T06:26:29+00:00","breadcrumb":{"@id":"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/porphyria.network\/IPPN\/2019\/10\/the-fda-approves-afamelanotide-for-epp\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/porphyria.network\/IPPN\/"},{"@type":"ListItem","position":2,"name":"The FDA approves afamelanotide for EPP!"}]},{"@type":"WebSite","@id":"https:\/\/porphyria.network\/IPPN\/#website","url":"https:\/\/porphyria.network\/IPPN\/","name":"International Porphyria Patient Network","description":"Welcome to the International Porphyria Patient Network","publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/porphyria.network\/IPPN\/#organization","name":"International Porphyria Patient Network","url":"https:\/\/porphyria.network\/IPPN\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/","url":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","contentUrl":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","width":671,"height":630,"caption":"International Porphyria Patient Network"},"image":{"@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765","name":"Editorial Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","caption":"Editorial Team"},"url":"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/"}]}},"_links":{"self":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/283"}],"collection":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/comments?post=283"}],"version-history":[{"count":5,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/283\/revisions"}],"predecessor-version":[{"id":291,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/283\/revisions\/291"}],"wp:attachment":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/media?parent=283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/categories?post=283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/tags?post=283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}